| 期刊論文| 1. | DiMasi, Joseph A.、Hansen, Ronald W.、Grabowski, Henry G.(2003)。The price of innovation: new estimates of drug development costs。Journal of Health Economics，22(2)，151-185。   | | 2. | Mueller, Janice M.(1998)。The evolving application of the written description requirement to biotechnological inventions。Berkeley Technology Law Journal，13，615-618。 | | 3. | Grabowski, Henry(2003)。Patents and New Product Development in the Pharmaceutical and Biotechnology Industries。Georgetown Public Policy Review，8，7-19。 | | 4. | Burk, Dan L.、Lemley, Mark A.(2002)。Is Patent Law Technology-Specific?。Berkeley Technology Law Journal，17，1155-1167。 | | 5. | DiMasi, Joseph A.(1991)。Cost of innovation in the pharmaceutical industry。Journal of Health Economics，10，107-142。 | | 6. | Adelman, David E.、Holman, Christopher M.(2010)。Misplaced Fears in the Battle over Affordable Biotech Drugs。IDEA，50，565-591。 | | 7. | Hay, Michael、Thomas, D. W.、Craighead, J. L.、Economides, C.、Rosenthal, J.(2014)。Clinical Development Success Rates for Investigational Drugs。Nature Biotechnology，32，40-51。 | | 8. | Greenspoon, Robert P.(2009)。Is the United States Finally Ready for a Patent Small Claims Court?。MINN. J. L. SCI. & TECH.，10。 | | 9. | Berndt, Ernst(2015)。Decline in Economic Returns from New Drugs Raises Questions about Sustaining Innovations。HEALTH AFF.，34(2)，245-252。 | | 10. | Grabowski, Henry(2011)。The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection。INT'L. J. OF THE ECON. OF BUS.，18(2)，161-176。 | | 11. | Holman, Christopher M.(2006)。Biotechnology's Prescription for Patent Reform。J. MARSHALL REV. INTELL. PROP. L.，5，318-347。 | | 12. | Shepherd, Joanna(2018)。Consolidation and Innovation in the Pharmaceutical Industry: The Role of Mergers and Acquisitions in the Current Innovation Ecosystem。J. HEALTH CARE L. & POL'Y，21(1)，1-28。 | | 13. | Shepherd, Joanna(2017)。The Prescription for Rising Drug Prices: Competition or Price Controls?。HEALTH MATRIX: J. OF L. MED.，27(1)，315-346。 | | 14. | Holman, Christopher M.(2015)。Developments in Synthetic Biology Are Altering the IP Imperatives of Biotechnology。VAND. J. ENT. & TECH. L.，17(2)，385-462。 | | 15. | Holman, Christopher M.(2010)。Maintaining Incentives for Healthcare Innovation: A Response to the FTC's Report on Follow-On Biologics。MINN. J.L. SCI. & TECH.，11(2)，755-800。 | | 16. | Grabowski, Henry(2011)。Data Exclusivity for Biologics。NATURE REV. DRUG DISCOVERY，10(1)，15-16。 | | 17. | Goldman, Dan P.、Joyce, Geoffrey F.、Zheng, Yuhui(2007)。Prescription Drug Cost Sharing: Associations with Medication and Medical Utilization and Spending and Health。J. AM. MED. ASS'N，298(1)，61-69。 | 學位論文| 1. | HOWE, KEVIN F.(2007)。The right to obtain patent protection on living material: the causes and consequences of the United States Supreme Court decision in the case of Diamond v. Chakrabarty(碩士論文)。Iowa State University。 | 圖書| 1. | Hughes, Sally Smith(2011)。Genentech: The Beginnings of Biotech。University of Chicago Press。 | | 2. | CHARLES, DANIEL(2008)。LORDS OF THE HARVEST: BIOTECH, BIG MONEY, AND THE FUTURE OF FOOD。 | 其他| 1. | (20120131)。Drug Pricing: Research on Savings from Generic Drug Use，http://www.gao.gov/assets/590/588064.pdf，(GAO-12-371R)。 | | 2. | U.S. FOOD & DRUG ADMIN(2017)。NOVEL DRUGS SUMMARY 2016，https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM536693.pdf。 | | 3. | Crouch, Dennis(20121220)。Moving Forward with a Small Claims Patent Court，http://www.patentlyo.com/patent/2012/12/moving-forward-with-a-small-claims-patent-court.html。 | | 4. | Terry, Mark(20160926)。Biotech vs. Big Pharma: Which Is the Better Place to work?，http://www.biospace.com/News/biotech-vs-big-pharma-which-is-the-better-place-to/432908。 | | 5. | AITKEN, MURRAY，KLEINROCK, MICHAEL(2017)。LIFETIME TRENDS IN BIOPHARMACEUTICAL INNOVATION，https://www.statnews.com/wp-content/uploads/2017/01/Lifetime_Trends_in_Biopharmaceutical_Innovation.pdf。 | | 6. | THOMAS, DAVID，WESSEL, CHAD(2016)。Emerging Therapeutic Company Investment and Deal Trends。 | | 7. | Finnegan, Joanne(20160114)。2015 Was a Record Breaker for M&A in Pharma, Medical and Biotech with Deals Worth 575 Billion，http://www.biospace.com/News/2015-was-a-record-breaker-for-ma-in-pharma-medical/405749。 | | 8. | MERGERMARKET(2017)。PHARMA, MEDICAL & BIOTECH TREND REPORT: Q1-Q4 2016，http://www.mergermarket.com/pdf/MergermarketTrendReport.Q1-Q42016.Pharma,Medical,Biotech.pdf。 | | 9. | ERNST AND YOUNG(2017)。EY M&A OUTLOOK AND FIREPOWER REPORT 2017。 | | 10. | GEILINGER, ULRICH(2016)。TRENDS IN US NEW DRUG APPROVALS。 | | 11. | DELOITTE(2017)。2017 GLOBAL LIFE SCIENCES OUTLOOK: THRIVING IN TODAY'S UNCERTAIN MARKET，https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2017-life-sciences-outlook.pdf。 | | 12. | PHRMA(2015)。CHARTPACK: PHARMACEUTICALS IN PERSP。 | | 13. | OFFICE OF THE ASSISTANT SEC'Y FOR PLANNING & EVALUATION, U.S. DEP'T OF HEALTH & HUMAN SERVS(20101201)。EXPANDING THE USE OF GENERIC DRUGS，http://aspe.hhs.gov/basic-report/expanding-use-generic-drugs#11。 | | 14. | PHRMA(2015)。Biopharmaceutical Research & Development: The Process Behind New Medicines。 | | 15. | Quinn, Gene(20110128)。The Cost of Obtaining a Patent in the US，http://www.ipwatchdog.com/2011/01/28/the-cost-of-obtaining-patent/id=14668/。 | | 16. | Quinn, Gene(20131120)。Prominent Independent Investors Unhappy with Innovation Act，http://www.ipwatchdog.com/2013/11/20/prominent-independent-inventors-unhappy-with-innovation-act/id=46436/。 | | 17. | IMS INSTITUTE FOR HEALTHCARE INFORMATICS(2013)。DECLINING MEDICINE USE AND COSTS: FOR BETTER OR WORSE? A REVIEW OF THE USE OF MEDICINES IN THE UNITED STATES IN 2012，http://static.correofarmaceutico.com/docs/2013/05/20/usareport.pdf。 | | 18. | PRICEWATERHOUSECOOPERS(2012)。ROM VISION TO DECISION: PHARMA 2020，http://www.pwc.com/gx/en/pharma-life-sciences/pharma2020/assets/pwc-pharma-success-strategies.pdf。 | | 19. | U. S. CONG. BUDGET OFF.(2002)。ISSUES IN DESIGNING A PRESCRIPTION DRUG BENEFIT FOR MEDICARE。 | | 20. | Bulik, Beth Snyder(20150615)。The Top-10 Most Advertised Prescription Drug Brands，http://www.fiercepharma.com/special-report/top-10-most-advertised-prescription-drug-brands。 | | 21. | MS INSTITUTE FOR HEALTHCARE INFORMATICS(2016)。PRICE DECLINES AFTER BRANDED MEDICINES LOSE EXCLUSIVITY IN THE U.S.，https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/PhRMA%20Generic%C20Price%C20Brief%20January%202016.pdf。 | | 22. | VISANTE(2016)。PHARMACY BENEFIT MANAGERS (PBMs): GENERATING SAVINGS FOR PLAN SPONSORS AND CONSUMERS。 | | 23. | U.S. GOV'T. CCOUNTABILITY OFFICE(2003)。Effects of Using Pharmacy Benefit Managers on Health Plans, Enrollees, and Pharmacies。 | |